Moore Capital Management, LP Glycomimetics Inc Transaction History

Moore Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$2.8 - $12.85 $140,000 - $642,500	-50,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$13.7 - $17.12 $685,000 - $856,000	-50,000 Reduced 50.0%	50,000 $720,000
Q2 2018 Aug 14, 2018	SELL	$14.63 - $19.19 $329,175 - $431,775	-22,500 Reduced 18.37%	100,000 $1.61 Million
Q1 2018 May 15, 2018	BUY	$16.06 - $25.35 $1.97 Million - $3.11 Million	122,500 New	122,500 $1.99 Million

25.6M

1.94M

153K

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $8.91M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.